Velocity Clinical Research Executive and Leadership Team

George Carey, the Chief Executive Officer at Velocity Clinical Research, directs the overarching corporate strategy and long-term vision for the organization. By aligning site capabilities with the evolving needs of global biopharmaceutical partners, the Chief Executive Officer ensures consistent growth across the clinical trial landscape. George Carey maintains direct oversight of executive leadership initiatives, fostering a culture of excellence that prioritizes patient recruitment and data integrity. This leadership role involves navigating complex regulatory environments while expanding the footprint of the company across North American markets. Through the implementation of scalable business models, the Chief Executive Officer drives operational efficiency and strengthens relationships with contract research organizations. Ultimately, Carey secures the competitive position of the firm by championing innovation in site-based research delivery and ensuring that all organizational objectives support the primary mission of accelerating medical development for patients worldwide.

Mike Zaranek, the Chief Financial Officer at Velocity Clinical Research, manages the fiscal health and capital allocation strategies of the enterprise. Overseeing financial reporting, budgeting, and long-term investment planning, the Chief Financial Officer ensures the company maintains the resources necessary to support rapid site expansion. Mike Zaranek evaluates market opportunities and financial risks, providing the data-driven insights required for informed decision-making at the board level. This role involves optimizing revenue cycles and managing relationships with institutional investors to fuel the growth of clinical trial infrastructure. By maintaining rigorous financial controls, the Chief Financial Officer supports the operational scale required for large-scale biopharmaceutical partnerships. Zaranek drives fiscal discipline across all departments, ensuring that every investment aligns with the core mission of enhancing patient access to clinical research while delivering sustainable value to stakeholders and partners throughout the global healthcare ecosystem.

Robert Buynak, the Physician and President at Velocity Clinical Research, directs the medical strategy and clinical oversight for the organization. Overseeing the scientific integrity of research protocols, the Physician and President ensures that all clinical trials maintain the highest standards of patient safety and data accuracy. Robert Buynak provides medical leadership to the research teams, guiding the implementation of complex study designs and therapeutic area expertise. This role involves collaborating with biopharmaceutical partners to align medical objectives with site capabilities, ensuring that the company remains at the forefront of clinical innovation. By bridging the gap between medical practice and research operations, the Physician and President drives the quality of trial execution. Buynak manages the medical staff and clinical standards, fostering a culture of excellence in patient care and scientific rigor. Ultimately, the Physician and President secures the reputation of the firm as a leader in clinical research by ensuring that every study meets rigorous medical benchmarks.

Kimberly Ballard, the Chief People Officer at Velocity Clinical Research, architects the human capital strategy and organizational culture necessary to support a high-performance workforce. Overseeing talent acquisition, employee development, and retention programs, the Chief People Officer ensures that the company attracts top-tier clinical and administrative professionals. Kimberly Ballard designs comprehensive training initiatives that align staff capabilities with the rigorous demands of clinical trial execution. This leadership role involves fostering an inclusive environment that promotes professional growth and operational excellence across all research sites. By implementing robust performance management systems, the Chief People Officer drives employee engagement and organizational alignment with the broader corporate mission. Ballard manages the complexities of a geographically dispersed workforce, ensuring that human resources policies support the operational scale of the business. Ultimately, the Chief People Officer secures the long-term success of the organization by building a resilient, skilled team dedicated to advancing medical research.

Brandi Lang, the Chief Legal Officer at Velocity Clinical Research, directs all legal affairs, regulatory compliance, and risk management strategies for the organization. Overseeing contract negotiations with biopharmaceutical partners and contract research organizations, the Chief Legal Officer ensures that all site operations adhere to stringent industry standards and legal requirements. Brandi Lang manages intellectual property protection and corporate governance, providing the necessary framework for secure and ethical clinical trial conduct. This leadership role involves navigating the complex legal landscape of medical research to mitigate liability and protect the interests of the company. By providing strategic counsel to the executive team, the Chief Legal Officer facilitates smooth operational expansion and partnership development. Lang drives compliance initiatives that uphold the integrity of clinical data and patient safety protocols. Ultimately, the Chief Legal Officer secures the legal foundation of the firm, enabling the business to focus on its mission of accelerating medical breakthroughs.

Nicholas Spittal, the Chief Operations Officer at Velocity Clinical Research, directs the daily execution of clinical trial site activities and operational workflows. Overseeing the integration of new research sites and the optimization of patient recruitment processes, the Chief Operations Officer ensures that all facilities meet the high standards required by biopharmaceutical customers. Nicholas Spittal manages the logistics of site-based research, focusing on efficiency, quality control, and the seamless delivery of trial data. This leadership role involves coordinating across departments to streamline operational procedures and enhance the overall patient experience during clinical studies. By implementing standardized operational protocols, the Chief Operations Officer drives productivity and ensures that research timelines remain on track. Spittal monitors performance metrics across the network, identifying opportunities for process improvement and resource allocation. Ultimately, the Chief Operations Officer secures the operational excellence of the company, enabling the successful completion of complex clinical trials on a national scale.